ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC will consider Ferriprox (deferiprone) as second-line treatment for transfusional iron overload; the company hopes for an endorsement of its patient and provider registries as well.
You may also be interested in...
Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow
Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.
ApoPharma's Ferriprox Clears FDA, But Needs Cardiac Safety Study
FDA's Oct. 14 accelerated approval of ApoPharma's second-line oral iron chelation therapy Ferriprox (deferiprone) includes a requirement that the sponsor conduct a post-marketing QT prolongation study, which the agency did not mention in background documents before the key advisory panel vote.
ApoPharma's Ferriprox Clears FDA, But Needs Cardiac Safety Study
FDA's Oct. 14 accelerated approval of ApoPharma's second-line oral iron chelation therapy Ferriprox (deferiprone) includes a requirement that the sponsor conduct a post-marketing QT prolongation study, which the agency did not mention in background documents before the key advisory panel vote.